From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly saw…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
Weight lost with GLP-1 drugs still subject to rebound after stopping treatment – Baltimore Sun
Weight lost with GLP-1 drugs still subject to rebound after stopping treatment Baltimore SunA pill helps you keep weight…
Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?
After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were…
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug,…
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
Last year, Eli Lilly (NYSE: LLY) made history when it became the first healthcare company to reach a…
Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor – Endpoints News
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor Endpoints NewsLilly to acquire Ajax…
Lilly’s Foundayo hits 1,390 prescriptions in debut week
April 17 (Reuters) – Eli Lilly’s newly launched obesity pill was prescribed 1,390 times in the U.S. as…
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the…